Stem Cell: August 2007

Friday, August 31, 2007

Keyword News: [stem cell]

Yahoo! Alerts

Friday, August 31, 2007 11:31 PM PDT

Geisinger plans stem cell primer course
Standard-Journal Fri, 31 Aug 2007 8:55 AM PDT
DANVILLE — Recent scientific and medical advancements have been among the most hotly debated topics in the public forum. Among the most contested issues is stem cell research. Religious groups, politicians and ill celebrities have all weighed in on the use of stem cells.

Ballot Proposal To Modify Missouri Amendment Protecting Embryonic Stem Cell Research In State Flawed, Opponents Say
Medical News Today Fri, 31 Aug 2007 4:11 AM PDT
The group Cures Without Cloning on Monday said it would change a proposal seeking to modify a Missouri constitutional amendment that protects human embryonic stem cell research after opponents said the proposal's definition of "human" would exclude people with common genetic abnormalities, the AP/Columbia Missourian reports (Taylor, AP/Columbia Missourian, 8/27). [click link for full article]

Heart Repair By Cardiomyocytes Produced From Human Embryonic Stem Cells
Medical News Today Fri, 31 Aug 2007 7:11 AM PDT
Geron Corporation (Nasdaq: GERN) has reported its scientists and collaborators have demonstrated that human embryonic stem cell (hESC)-derived cardiomyocytes improve heart function when transplanted after myocardial infarction. [click link for full article]

A Stem-Cell Primer
The Motley Fool Fri, 31 Aug 2007 12:54 PM PDT
Public funding from states could help the companies doing the research.

Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation And Self Renewal Of Human ...
Medical News Today Fri, 31 Aug 2007 1:13 AM PDT
Novocell Inc., a stem cell engineering company, announced research findings that for the first time identify two prominent cancer cell signaling pathways as essential for the efficient proliferation and self-renewal of human embryonic stem cells (hESCs). [click link for full article]

Group alters language of proposal
Belleville News-Democrat Fri, 31 Aug 2007 4:15 AM PDT
A group seeking to restrict embryonic stem cell research in Missouri says it has filed new language in its effort to get the issue before voters.

SCS shrugs off bigger loss
Edinburgh Evening News Fri, 31 Aug 2007 4:47 AM PDT
STEM Cell Sciences, the Edinburgh headquartered biotech group, saw its operating loss over the first half of the year widen to £1.75 million, from £1.12m a year ago while revenues slipped to £460,000, from £494,000.

Iran finds formula to heal leishmaniasis nodosa scar
mehrnews.com Fri, 31 Aug 2007 10:33 AM PDT
TEHRAN, Aug. 31 (MNA) – Iran registered its name in the world's medical book after finding treatment of leishmaniasis nodosa scar and skin restoration by stem cell injection, said Skin Disease and Leishmaniasis Research Center head here on Friday.

Osiris Therapeutics to Present at the Thomas Weisel Partners Healthcare Conference 2007
Business Wire via Yahoo! Finance Fri, 31 Aug 2007 5:00 AM PDT
COLUMBIA, Md.----Osiris Therapeutics, Inc. , a leading stem cell therapeutic company, announced today that C. Randal Mills, Ph.D., President and CEO, will present at the Thomas Weisel Partners Healthcare Conference in Boston.

Yard sale to aid boy with rare sight condition
Bowling Green Daily News Fri, 31 Aug 2007 2:14 AM PDT
A large yard sale at 6698 Nashville Road on Sept. 6-8 will benefit Jackson Blackford. Jackson was born blind from a rare condition called optic nerve hypoplasia. He will travel to China in mid-October for stem cell transplants.

See more news stories that match my keyword

You received this email because you subscribed to Yahoo! Alerts. Use this link to unsubscribe from this alert. To change your communications preferences for other Yahoo! business lines, please visit your Marketing Preferences. To learn more about Yahoo!'s use of personal information, including the use of web beacons in HTML-based email, please read our Privacy Policy. Yahoo! is located at 701 First Avenue, Sunnyvale, CA 94089.

Thursday, August 30, 2007

Keyword News: [stem cell]

Yahoo! Alerts

Yahoo! News - My Alerts - Edit Alert

Thursday, August 30, 2007 11:31 PM PDT

Stem Cell reports wider loss of £1.75m
The Herald Thu, 30 Aug 2007 1:38 PM PDT
Stem Cell Sciences, the pioneering Edinburgh University spin-out which aims to cure degenerative disorders, posted a wider first-half loss, but it said it expects to introduce its human neural stem cell platform before the end of the year.

Lawmakers praise stem cell funding
The Courier News Thu, 30 Aug 2007 2:19 AM PDT
In a move completely contrary to the contentious atmosphere that has surrounded Springfield in recent months, local lawmakers on Wednesday commended a newly signed measure to provide state funding for embryonic stem cell research.

Thai stem cell researchers treat diabetic wounds
MCOT - TNA English News Thu, 30 Aug 2007 7:29 AM PDT
BANGKOK, Aug 30 (TNA) - Thai medical researchers and physicians have achieved success in treating foot wounds of diabetes patients with their own stem cells, according to an announcement from Thailand's National Innovation Agency chief Supachai Lorlowhakarn.

Experimental anti-cancer drug made from corn lillies kills brain tumor stem cells
EurekAlert! Thu, 30 Aug 2007 12:52 PM PDT
A drug that shuts down a critical cell-signaling pathway in the most common and aggressive type of adult brain cancer successfully kills cancer stem cells thought to fuel tumor growth and help cancers evade drug and radiation therapy, a Johns Hopkins study shows.

Experimental Anti-cancer Drug Kills Brain Tumor Stem Cells
Science Daily Thu, 30 Aug 2007 2:04 PM PDT
A drug that shuts down a critical cell-signaling pathway in the most common and aggressive type of adult brain cancer successfully kills cancer stem cells thought to fuel tumor growth and help cancers evade drug and radiation therapy, a Johns Hopkins study shows. The drug is derived from corn lillies.

Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human ...
PR Newswire via Yahoo! Finance Thu, 30 Aug 2007 9:39 AM PDT
Novocell Inc., a stem cell engineering company, today announced research findings that for the first time identify two prominent cancer cell signaling pathways as essential for the efficient proliferation and self-renewal of human embryonic stem cells .

Sheriff Lee Explores Transplant Possibilities
WDSU TheNewOrleansChannel.com via Yahoo! News Thu, 30 Aug 2007 2:25 PM PDT
Jefferson Parish Sheriff Harry Lee is exploring the possibility of a stem cell or bone marrow transplant as he battles leukemia.

Reprogrammed Embryonic Stem Cells Identified By Appearance Alone
Medical News Today Thu, 30 Aug 2007 11:11 AM PDT
Some scientific results are hard to spot, especially in genetic research. Often scientists are unable to physically see if the gene they inserted into a cell has produced the desired trait. To overcome this problem researchers use various genetic markers that contain pieces of foreign DNA that cause cells to, for example, glow when exposed to ultraviolet light. [click link for full article]

2007/08/27
New Straits Times Thu, 30 Aug 2007 8:40 PM PDT
Dr Buckley is conducting research into Parkinson's disease. Alumni of King's College, London, will get together at a dinner next week. FRANCIS DASS talks to the college's representative, scientist Noel Buckley who is involved in stem cell research.

SCS set for revenue rise despite sales fall
The Scotsman: Business Thu, 30 Aug 2007 6:06 PM PDT
STEM Cell Sciences (SCS), the biotechnology company, is on course to deliver increased full-year revenues despite a dip in first-half sales.

See more news stories that match my keyword

94. TRISTEM: http://www.tristemcorp.com/

The TriStem Group has been set up by Mr.Ghazi Dhoot and Dr. Ilham Saleh Abuljadayel to further research and develop its retrodifferentiation technology which is used to create stem cells from mature adult cells. The retrodifferentiation technology is based on the results of 12 years of research and currently TriStem is the only company that owns, and is in the process of commercialising, this technology. The main advantage of TriStem's new process over existing methods of harvesting stem cells is that it provides large quantities of stem cells which are by definition DNA matched and, therefore, bypasses the political and ethical issues concerned with therapeutic cloning.

TriStem believes that there is a wide ranging potential for clinical, pharmaceutical and biotechnological applications for its proprietary stem cell technology. For example, novel compounds could be screened for their retrodifferentiation ability in order to manipulate a specific cell type in the body and such cells can be studied for research purposes to better understand stem cell biology.

Stem cells are being investigated as therapeutics for a wide variety of applications. TriStem will initially evaluate the clinical potential of its retrodifferentiation stem cell technology in aplastic anaemia, thalassemia and leukaemia patients that would ordinarily require a blood marrow transplant (BMT). Leukaemia, a disease which resulted in an estimated 22,100 deaths in the United States alone in 1999, is also a disease area with a wide unmet clinical need and a large potential for expedited clinical development. TriStem will also in due course explore the application of its technology in other areas of oncology such as lymphoma, myeloma and solid tumours. In addition, the technology should over time be employed in the treatment of a much wider range of illnesses such as spinal cord injury, diabetes and heart disease.

Please contact us with any requests for further
information: info@tristemcorp.com

Or write to us
571, Finchley Road
Unit 320
London NW3 7BN
United Kingdom

93. TIGENIX: www.tigenix.com

TiGenix is a biomedical company operating at the cutting edge of regenerative medicine. Its core mission is to provide a comprehensive solution for damaged and osteoarthritic joints through the combination of innovative cellular therapies and locally delivered therapeutics. We are constantly on the lookout to strengthen our team. If you are interested and believe you can contribute to our success, don't hesitate to contact us at careers@tigenix.com.

The Company's first product, ChondroCelect, is an improved ACI product, the first to incorporate identity characterization based on in vivo biological function. Designed to guarantee formation of stable hyaline cartilage in vivo, ChondroCelect aims at true functional repair of the demaged joint surface.

Rebekka Declercq,

TiGenix,

Technologielaan 3,

3001 Leuven.

rebekka.declercq@tigenix.com

92. THERAVITAE: www.theravitae.com

TheraVitae is a multi-national healthcare company focused on using the patient’s own adult stem cells to treat a variety of disorders, especially cardiovascular diseases. We collaborate with eminent physicians and scientists who are affiliated with well-known medical and academic institutions. We are committed to make the benefits of adult stem cell therapy accessible to all with integrity, safety and compassion.

VesCell™ – Adult Stem Cell therapy for Heart Disease

Cardiologists and cardiac surgeons are using VesCell™ to treat no-option patients suffering from Ischemic Heart Disease (Coronary Artery Disease), Cardiomyopathy and End-stage Heart Failure by relieving debilitating symptoms such as severe angina pectoris (chest pain) and shortness of breath. Read More

VesCell™ – Adult Stem Cell Therapy for PAD (Peripheral Artery Disease)

VesCell™ PAD is the latest adult stem cell technology developed by TheraVitae. It is using patients’ stem cells to treat severe disease of the lower limbs, enriching blood flow to the affected area and thus avoiding possible amputation.

Israel Office:

7 Pinhas Sapir Street
P.O. Box 4049,
Ness Ziona 74140,
Israel

Tel: + (972) 8940-9170
Fax: + (972) 8940-9167

Thailand Office:

36/72 PS Tower, 21st Floor,
Sukhumvit 21 Rd.
Klongtoey-Nua,Wattana,
Bangkok, Thailand 10110
E-Mail : enquiries@TheraVitae.com

USA Office:

1 Galleria Tower 13355 Noel, Suite 1700,
Dallas, Texas 75240, USA, Email:pr@TheraVitae.com

91. THERADIGM: www.theradigm.com

Theradigm, Inc., a portfolio company of Toucan Capital Fund II, is developing cell-based therapies for treatment of the central nervous system (CNS) disorders. Two different types of cells (1) neural stem cells and (2) bone marrow stromal cells may be applied alone or in combination to constitute unique therapies. Theradigm has a substantial intellectual property base covering use of these cells in CNS applications.

Theradigm, Inc. is an equal opportunity employer. Theradigm, Inc. is committed to equal employment opportunities in all employment practices and decisions including: recruitment, hiring, promotion, training, compensation, and disciplinary action with regard to the terms and conditions of employment. Theradigm, Inc. does not discriminate on the basis of race, religion, national origin, color, age, sex, disability, veteran status, sexual orientation, genetic information, or any other legally protected characteristic. Employees are our most valuable resource. We are committed to fostering an environment where recognition, innovation, communication, and an entrepreneurial spirit are encouraged and rewarded. We attract and retain qualified candidates by providing competitive cash compensation and benefits package. It is Theradigm's policy to provide employees with significant opportunities to develop professionally by providing them with tuition reimbursement and the opportunity to attend professional conferences.

Human Resources
1448 S. Rolling Road
Baltimore, MD 21227
hr@cognatetherapeutics.com

Smita Savant-Bhonsale
Vice President and General Manager ssavant@theradigm.com

Amanda Hendricks Human Resources
ahendricks@theradigm.com

Location

Theradigm, Inc. -East
1448 S. Rolling Road
Baltimore, MD 21227
(410) 455-5697 - Phone
(410) 455-5551 – Fax

Stem Cells Express: Newly Published Papers Online

[StemCellInformation] # 362 Wednesday, August 29, 2007 - SOME VERY BAD POEMS ABOUT STEM CELL RESEARCH

# 362 Wednesday, August 29, 2007 - SOME VERY BAD POEMS ABOUT STEM CELL RESEARCH

SOME VERY BAD POEMS ABOUT STEM CELL RESEARCH

(Inflicted on the audience at a Research for Cure fundraiser, August 26, 2007)

by Don C. Reed, www.stemcellbattles.com

WHO NEEDS STEM CELL RESEARCH?

Is it you? Or is it me?

A member of our family?

One hundred million citizens, in America alone;

Enduring chronic illness or injury, with courage, or a groan.

Think of someone you love, incurably ill,

They will not get better, not with drug, shot, or pill.

They have cancer, Alzheimer?s, spinal cord injury:

A chronic disease, or a disability.

And every one of those people, man or woman, boy or girl,

Has a family affected?which means everybody, all across the world.

What emotional, physical, financial burdens we share;

Chronic disease is three-quarters of the cost of everyone?s health care.

WHAT DO WE WANT FROM STEM CELL RESEARCH?

We want an end to arthritis with its grinding pain,

An end to stomach ulcers and their stabbing shoots of flame.

Open the living tomb of Parkinson?s, no more blindness from diabetes,

Free the frozen limbs of paralysis, stop dozens more disabilities.

And while we?re at it, why don?t we

Regenerate the economy?

READY FOR STEM CELL CHANGE

We have tried every known medicine, we are at the end of our rope;

We are tired of doctors telling us, we must abandon hope.

Standard practice cannot cure us, despite the best of will.

So let us look to the science lab, and the tiniest of cells.

Stem cells, invisible, amazing, and real.

A medical advance, our bodies to heal.

To solve the problem, go to the stem, the very root,

If we were computers, we would have to reboot.

ADULT VERSUS EMBRYONIC STEM CELLS

Adult and embryonic stem cells, each has its own potential,

Each is useful, each is good, both are sometimes controversial.

There are some who say adult stem cells can build a body bionic;

And they would STOP the other stem cell research, denying embryonic.

Adult stem cells are found in our bodies, after most of our growing is done.

But they are not built to multiply fast, and their purpose is really just one.

They are miniature repair kits, and we all are glad they exist.

But to call them the equal of embryonic-- is an illusion we must resist.

Adult stem cells are useful indeed, like a bandage for minor injury.

But one does not apply a band-aid, when it is time for major surgery.

Adult stem cells regenerate cells, but slowwwwwly, like a bald man growing hair;

But embryonic cells grew every portion of us, not just isolated cells here and there.

Adult stem cells, like gift certificates, are specialized, and sometimes rare.

Embryonic stem cells become anything, like cash money, spendable everywhere.

Adult stem cells help to heal little cuts, like zippers, making scars.

But the power of adult next to embryonic? Like a flashlight next to a star.

ARE WE CLONING BABIES?

Before every medical advance,

There is always the darkness of ignorance.

Misunderstandings delay us, bog us down in endless strife;

And the biggest fear is this; that stem cell research means creating a life.

This is false, false, false-- there are no cloned babies.

Neither kids nor pregnancies involved, on this there are no maybies.

If somebody crooked tried to clone a child, that crook belongs in jail;

Do not pass go, expect massive fines, no one should post their bail.

Cloning is for gardeners, who cut ?slips? and plant them, every day.

But we don?t need it for babies, we can make them the old fashioned way.

Reproductive cloning (like Dolly the sheep) must never be allowed.

But SCNT, which is stem cells for cure?of that we can all be proud.

Cells, cells, nothing but cells, that is what we are here for;

Cells to bring hope to those we love, the suffering ones we care for.

To take a cell from a diseased body, and fix it, make it right;

And use it to heal its owner? That is a step forward, into the light.

ON THE DIFFICULTY OF RHYMING SCNT

There is a technique called SCNT, which everyone will someday understand;

It will be funded by Congress, praised by Presidents, and every leader in the land.

It has, in fact, already been praised by former Presidents Gerald Ford and Jimmy Carter;

And as for the current occupant of the White House? He hasn?t-- but he ought?a!

Like DNA research, also once opposed, (until it made insulin),

SCNT is a wonderful technique, for the life-saving effort we are in.

To take a cell out of a person, and merge it with an emptied egg,

May help us defeat diabetes, may prevent the amputation of a leg.

Instead of transplanting a kidney, why not re-grow one?s own?

Or study a disease, in Petri dish cells? About that no one should moan.

To make disease-specific stem cell lines, (and lower drug testing costs),

And build non-rejectable replacement organs? SCNT must not be lost.

Should we grow new skin for a burn victim, restore motion to the paralyzed?

End ALS, blindness, deafness, cancer, and Aids?would that not be wise?

Somatic Cell Nuclear Transfer, it is hard to find rhymes for that?

But SCNT possibilities-- in potential it is so fat!

ON STEM CELL ADVOCATES, AND BAD POETRY

We are all in this together; each of us will play a part,

And our children will remember how we helped a great science to start.

And now it is time, thank goodness, for these awful poems to end.

Thank you for listening so patiently, and for helping our scientists to win.

Don Reed

www.stemcellbattles.com

__._,_.___

Messages in this topic (1) Reply (via web post) | Start a new topic

Messages | Calendar

Change settings via the Web (Yahoo! ID required)
Change settings via email: Switch delivery to Daily Digest | Switch format to Traditional
Visit Your Group | Yahoo! Groups Terms of Use | Unsubscribe

__,_._,___

BioE Update 08.07 Issue

Issue 4 Volume 2

August 2007

Orthopedic Applications of the Multi-Lineage Progenitor Cell (MLPC)

What is the MLPC? MLPC

MLPC are a phenotypically and genetically unique population of human stem cells recovered from post-partum umbilical cord blood that are capable of extensive self-renewal and multi-lineage differentiation including cells representing all the commonly described embryonic layers.

How could these cells contribute to the development of therapeutics for orthopedic and bone degenerative diseases?

In order to overcome the limitations of traditional structural engineering approaches to orthopedic and osteo-degenerative diseases, new therapeutics in current orthopedic practice and in-development are combining state of-the-art structural engineering and metallurgy, as well as new bio-compatible materials: osteo-conductive (support the colonization by bone-forming cells and provide raw materials for new bone formation) and osteo-inductive (stimulate new bone growth) compounds, and now cells (which have both osteo-conductive and osteo-inductive properties). One of the current therapeutic strategies being developed revolve around the integration of osteo-conductive (extracellular matrixes, de-mineralized bone matrix) and osteo-inductive materials (cells, Bone morphogenic protein (BMP). MLPC present a unique cellular opportunity for this application in their unique clonability, controllability, expansibility, ability to remodel osteo-conductive materials, as well as their osteo-inductive and -conductive properties.

The ability of MLPC to develop into osteo-inductive osteoblasts, endothelial cells which contribute to vascularization of bone tissue and stromal cells known to aid in blood stem cell support could provide an enhanced pathway to accelerated annealing, integration, and load-bearing ability of grafts. Combining osteo-conductive materials with MLPC would mean that cells would no longer have to colonize the graft from outside because the osteo-inductive cells would be integral to the graft prior to implantation. MLPC have been found to be biologically Osteoblast compatible with a number of materials commonly used in Orthopedic medicine as well as other materials, including tri-calcium phosphate, hydroxyapatite, alumina, titania, collagen, laminin, fibronectin, and cellulose. This compatibility provides a wide platform towards the co-development of MLPC and optimized biocompatible structures specific for each differentiated cell type.

For more information on the MLPC and its potential applications please contact a BioE Business Development Manger

Join BioE at these upcoming tradeshows:

Termis EU

September 4 - 7, 2007

London, England

http://www.termis.org/eu2007/index.php

BIO Mid-America Venture Forum

September 24 - 26, 2007

Milwaukee, Wisconsin

http://www.midamerica.bio.org

The Burrill Stem Cell Summit

October 2 - 3, 2007

Boston, Massachusetts

http://www.thestemcellsummit.com

Featured Article in Burrill Stem Cell Report, Fall 2007-

"The Multi-Lineage Progenitor Cell: An Enabling Tool for Developing Cellular and Biologic Therapies" by Carol Buchert, MT (ASCP), Vice President of Operations, Sales/Marketing, BioE, Inc.

World Congress on Regenerative Medicine

October 18 - 20, 2007

Leipzig, Germany

http://www.regmed.org

AABB Annual Meeting & TXPO 2007

October 20 - 23, 2007

Anaheim, California

http://www.aabb.org

NASS : National Association of Spine Specialists

October 23 - 27, 2007

Austin, Texas

http://www.spine.org/am07/index.html

American Society of Hematology Annual Meeting (ASH)

December 8 - 11, 2007

Atlanta, Georgia

http://www.hematology.org

BioE Employee Wins Roche Contest

In July of 2007 Roche Applied Sciences sent a direct mailer to customers that were noted to utilize qPCR in their labs. The direct mailer directed customers to read through a brochure/flyer on Roche Applied Sciences Gene Expression solutions (LightCycier 480, MagNA Pure, manual NAPI, qPCR reagents, and UPL). The recipients were then asked to go online and answer 4 "simple" questions about the brochure/flyer where those that answered all 4 questions correctly were entered into a drawing for sponsorship to the scientific meeting of their choice. The prizes were $1000 (1st place), $750 (2nd place), and $500 (3rd place).

Mona Schmidt, a Molecular Biology Scientist for BioE won the third place prize. Mona came to BioE from 3M bringing years of experience in genetics and biotechnology. Mona is currently the head of the Molecular Analysis Laboratory at BioE whose primary focus is to analyze changes in gene expression of the Multi-Lineage Progenitor Cell as it moves along the path of chosen differentiations.

Congratulations to Mona and thanks to Roche Applied Sciences for sponsoring attendance to an upcoming scientific meeting.

Interested in Purchasing the MLPC?

Click here to Contact a BioE Business Development Manager

www.bioe.com

Is your cord blood bank interested in improved cell recovery?

If so, click here to learn what PrepaCyte®-CB cord blood processing equipment can do for you.

Looking for a deal? Find great prices on flights and hotels with Yahoo! FareChase.

World Stem Cell Summit 2010

Friday, August 31, 2007

Thursday, August 30, 2007

Any Comments ?.......

Stem Cell Researchers

National and International Bioethical Bodies

Study and work opportunities (MS, PhD, PostDoc)

World Time

Student Society For Stem Cell Research - www.ssscr.org

Student Society For Stem Cell Research

Contact

Blog Archive

Labels

World StemCell Societies, Forums and Networks

World StemCell Institutes, Centres and Foundations

World Stem Cell Banks

Bone marrow Transplantation and Donation

StemCell Therapy : Health Service

Stem cell map

Stem Cell Therapy Clinics, Stem Cell Treatment Available Now

StemCells - The PORTAL

Stem Cell Research Blog

Cell Stem Cell

Stem Cell News

Latest Headlines - Stemcells.net

Swiss Stem Cells Network - breaking news

North East England Stem Cell Institute

The Niche

StemCells - The PORTAL

Nature Reports: Stem Cells

California Stem Cell Report

ScienceDaily: Stem Cell News

UW-Madison News: Stem cells

Latest Genetics Stem Cells News

Journal of Cell Science current issue

The Journal of Cell Biology current issue

Stanford University School of Medicine News

Cancer Cell International - Latest articles

Cell

Nature Reviews Molecular Cell Biology

Immunology and Cell Biology

Nature Cell Biology

Nature Immunology

Cell Research

Cell Death and Differentiation

BMC Cell Biology - Latest articles

Nature Reviews Immunology

CellTherapyNews: Newsletters

MSRC Stem Cell Research & Treatment

BioPOD - The biology podcast from the University of Edinburgh

National Institutes of Health (NIH) Podcast

National Institutes of Health (NIH) Vodcast

MedlinePlus Health News

StemCellPatents.com News

StemCellPatents.com Job Board

StemCellPatents.com Recently Added Stem Cell Patents

BBC News Player | Health

BBC News | Health | UK Edition

TIME: Top Science and Health Stories

Johns Hopkins Medicine News

All Medical Research Council News Feeds

CNN.com - Health

ABC News: Health

MSNBC.com: Health

NYT > Stem Cells

NYT > Health

Scientific American - Health

CTV Health

UCSF Medical Center

UCTV Podcasts Presents: Video Podcasts

NPR: Health & Science

NPR Topics: Health & Science

Health News: CBSNews.com

Search Results for : "Human Fertilisation and Embryology Act 1990"

The Hindu - Science & Technology

FindArticles - Search Alert - Stem Cells

Stem Cell Books (Can Download)

ORKUT: SSSCR

India

USA